Eli Lilly and Company acquires LimmaTech Biologics for up to $780 million / Bio-Technopark Schlieren-Zürich / beUnity

Eli Lilly and Company acquires LimmaTech Biologics for up to $780 million

In English
Auf Deutsch

Bio-Technopark Schlieren-Zürich Offizielles